RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia

Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia

(2014) Ajay Abraham et al.   ANNALS OF HEMATOLOGY

RRM1andRRM2pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients

(2013) Xueyuan Cao et al.   PHARMACOGENOMICS

Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma

(2012) Hao Xie et al.   CANCER

CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations

(2012) Joseph Ciccolini et al.   PHARMACOGENOMICS

Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia

(2012) Ajay Abraham et al.   PHARMACOGENOMICS

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia

(2011) S. Schwind et al.   BLOOD

Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis

(2011) Mayur Parihar et al.   LEUKEMIA & LYMPHOMA

Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer

(2011) Liang Li et al.   Pharmacogenetics and Genomics

FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression

(2009) Guilan Jin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

(2009) Daniela Cilloni et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies

(2009) Joseph Ciccolini et al.   JOURNAL OF CLINICAL ONCOLOGY

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival

(2009) U Mahlknecht et al.   LEUKEMIA

Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity

(2008) C. M. Hartford et al.   BLOOD

Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia

(2008) Deepika Bhatla et al.   BRITISH JOURNAL OF HAEMATOLOGY

Molecular Classification of Acute Myeloid Leukemia: Are We There Yet?

(2008) Jerald P. Radich   JOURNAL OF CLINICAL ONCOLOGY